id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2006-E-0197-0011,FDA,FDA-2006-E-0197,Letter from U.S. Patent and Trademark Office to Bristol-Myers Squibb Co.,Other,Letter(s),2008-10-29T04:00:00Z,2008,10,2008-10-29T04:00:00Z,,2025-12-19T00:55:02Z,,0,0,09000064807736b5
FDA-2006-E-0197-0010,FDA,FDA-2006-E-0197,Notice of Final Determination from U.S. Patent and Trademark Office to Bristol-Myers Squibb Company,Other,Letter(s),2008-10-29T04:00:00Z,2008,10,2008-10-29T04:00:00Z,,2025-12-19T00:50:34Z,,0,0,090000648068ce0e
FDA-2006-E-0197-0008,FDA,FDA-2006-E-0197,Application for Patent Term Extension from Bristol-Myers Squibb Company,Other,Application,2008-10-29T04:00:00Z,2008,10,2008-10-29T04:00:00Z,,2025-12-19T00:46:37Z,,0,0,0900006480450ef2
FDA-2006-E-0197-0009,FDA,FDA-2006-E-0197,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2008-10-29T04:00:00Z,2008,10,2008-10-29T04:00:00Z,,2025-12-19T00:48:12Z,,0,0,090000648068cdf4
FDA-2006-E-0197-0007,FDA,FDA-2006-E-0197,Determination of Regulatory Review Periods for Purposes of Patent Extension; SPRYCEL--New Drug Applications 2 1-986 and 22-072,Notice,General Notice,2007-05-25T04:00:00Z,2007,5,2007-05-25T04:00:00Z,,2025-12-19T00:33:26Z,E7-10089,0,0,0900006480450efc
FDA-2006-E-0197-0006,FDA,FDA-2006-E-0197,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2007-05-17T04:00:00Z,2007,5,,,2025-12-19T00:29:59Z,,0,0,0900006480450efb
FDA-2006-E-0197-0005,FDA,FDA-2006-E-0197,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2007-03-06T05:00:00Z,2007,3,,,2025-12-19T00:14:46Z,,0,0,0900006480450efa
FDA-2006-E-0197-0004,FDA,FDA-2006-E-0197,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2007-01-26T05:00:00Z,2007,1,,,2025-12-19T00:08:24Z,,0,0,0900006480450ef9
FDA-2006-E-0197-0003,FDA,FDA-2006-E-0197,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2007-01-26T05:00:00Z,2007,1,,,2025-12-19T00:06:08Z,,0,0,0900006480450ef8
FDA-2006-E-0197-0001,FDA,FDA-2006-E-0197,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2006-12-15T05:00:00Z,2006,12,,,2025-12-19T00:01:54Z,,0,0,0900006480450eec
FDA-2006-E-0197-0002,FDA,FDA-2006-E-0197,Notice of Informalities from U.S. Patent and Trademark Office to Bristol-Myers Squibb Company,Other,Letter(s),2006-12-15T05:00:00Z,2006,12,,,2025-12-19T00:04:01Z,,0,0,0900006480450ef7